drugset / Trial / NCT00000157

Randomized Trial of Aspirin and Cataracts in U.S. Physicians

NCT00000157 ↗

Phase 3 Terminated National Eye Institute (NEI)
RandomizedPrevention

Summary

To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery.

Timeline

Start
1982-04
Primary completion
—
Completion
1988-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg —

Indications